Immunology: Monoclonal Antibodies at Age 20: Promise at Last?

doi:10.1126/science.270.5238.915

Account Information

Guest Alerts | Access Rights | My Account | Sign In

Site Navigation

Article Views

Summary
Full Text (PDF)

Article Tools

My Science

More Information

Related Jobs from ScienceCareers

Science 10 November 1995:
Vol. 270. no. 5238, pp. 915 - 916
DOI: 10.1126/science.270.5238.915

Prev | Table of Contents | Next

Research News

Stephen S. Hall

When they were first produced 2 decades ago, monoclonal antibodies were enthusiastically touted as "magic bullets" that would find wide application in medical therapeutics and diagnostics. But a variety of problems including severe immune reactions prevented them from living up to the early hype. A recent conference on monoclonals and cancer therapy suggests, however, that some of the difficulties are slowly being overcome.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:

Delivery of Systemic Chemotherapeutic Agent to Tumors by Using Focused Ultrasound: Study in a Murine Model.: E. L. Yuh, S. G. Shulman, S. A. Mehta, J. Xie, L. Chen, V. Frenkel, M. D. Bednarski, and K. C. P. Li (2005)
Radiology 234, 431-437
| Abstract » | Full Text » | PDF »

Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules.: P. A. Netti, L. M. Hamberg, J. W. Babich, D. Kierstead, W. Graham, G. J. Hunter, G. L. Wolf, A. Fischman, Y. Boucher, and R. K. Jain (1999)
PNAS 96, 3137-3142
| Abstract » | Full Text » | PDF »

A Monoclonal Antibody against Rat Calcitonin Inhibits the Growth of a Rat Medullary Thyroid Carcinoma Cell Line in Vitro.: R. Zhang and L. J. DeGroot (1997)
Endocrinology 138, 1697-1703
| Abstract » | Full Text » | PDF »

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin�superfamily.: J.�K. Heath, S.�J. White, C.�N. Johnstone, B. Catimel, R.�J. Simpson, R.�L. Moritz, G.-F. Tu, H. Ji, R.�H. Whitehead, L.�C. Groenen, et al. (1997)
PNAS 94, 469-474
| Abstract » | Full Text » | PDF »